Drug Trial Radar · NCT02600494
Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression
Last checked: Nov 20, 2026Latest source record: Nov 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
554
Actual
Start
Dec 15, 2015
Primary completion
Jan 28, 2019
Study completion Jul 24, 2019
Sponsor
- Lead sponsor
- Intra-Cellular Therapies, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 9, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate the efficacy and safety of ITI-007 (Lumateperone) in patients diagnosed with Bipolar I or Bipolar II disorder having a major depressive episode. The study will be conducted in two parts, Part A and Part B. Part A is a randomized, double-blind, placebo-controlled study. In Part B, patients who safely complete participation in part A may be enrolled in an open-label extension.
Conditions
- Bipolar Depression
Interventions
ITI-007 (Lumateperone)Drug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Day 43 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total ScoreTime frame: 6 weeks
Locations
55 sites in 1 country. Site status is shown where the registry gives one.
Clinical Site
Little Rock, Arkansas
Clinical Site
Rogers, Arkansas
Clinical Site
Cerritos, California
Clinical Site
Culver City, California
Clinical Site
Garden Grove, California
Clinical Site
Lemon Grove, California
Clinical Site
National City, California
Clinical Site
Oakland, California
Clinical Site
Oceanside, California
Clinical Site
Orange, California
Clinical Site
Pico Rivera, California
Clinical Site
Riverside, California
Clinical Site
San Diego, California
Clinical Site
San Marcos, California
Clinical Site
Santa Rosa, California
Clinical Site
Colorado Springs, Colorado
Clinical Site
Bradenton, Florida
Clinical Site
Fort Myers, Florida
Clinical Site
Jacksonville, Florida
Clinical Site
Lauderhill, Florida
Clinical Site
Miami, Florida
Clinical Site
North Miami, Florida
Clinical Site
Orlando, Florida
Clinical Site
Atlanta, Georgia
Clinical Site
Chicago, Illinois
Clinical Site
Hoffman Estates, Illinois
Clinical Site
Lake Charles, Louisiana
Clinical Site
Baltimore, Maryland
Clinical Site
Boston, Massachusetts
Clinical Site
O'Fallon, Missouri
Clinical Site
St Louis, Missouri
Clinical Site
Las Vegas, Nevada
Clinical Site
Berlin, New Jersey
Clinical Site
Cherry Hill, New Jersey
Clinical Site
Marlton, New Jersey
Clinical Site
Toms River, New Jersey
Clinical Site
Brooklyn, New York
Clinical Site
Cedarhurst, New York
Clinical Site
New York, New York
Clinical Site
Rochester, New York
Showing 40 of 55 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.